Stein Gold Linda, Kwong Pearl, Draelos Zoe, Arekapudi Krysten Lisella, Levy-Hacham Ofra, Erlich Maya, Desai Seemal R
Dr. Stein Gold is with the Department of Dermatology at Henry Ford Health System in Detroit, Michigan.
Dr. Kwong is with HCA Healthcare at Mercer University School of Medicine in Orange Park, Florida, and Solutions Through Advanced Research, Inc. in Jacksonville, Florida.
J Clin Aesthet Dermatol. 2023 May;16(5):26-34.
Topical therapies remain the mainstay in treating patients with acne and rosacea. However, emerging real-world evidence demonstrates that desired treatment outcomes might not be achieved if patient satisfaction and adherence are low. Poor tolerability of active drug(s) and vehicle components and/or the drug delivery system could negatively influence adherence. Additionally, adherence might be lower with complex treatment regimens involving the application of multiple topical formulations. Optimizing vehicle tolerability and simplifying regimens that use fixed-dose combinations may improve treatment outcomes, better patient satisfaction, and reduce overall treatment costs. This qualitative review discusses several innovative drug delivery technologies and formulations aimed at improving patient satisfaction and adherence.
The authors conducted a search of current and emerging topical drug delivery technologies used in clinical studies, reviewed primary literature on the chemical characteristics of topical dosage forms, and compared the impacts on treatment outcomes for acne and rosacea.
This article provides insight into innovative vehicles and drug delivery systems that have emerged allowing for fixed-dose combinations of incompatible active drugs and improving the tolerability of historically irritative active ingredients.
Further research is needed to fully highlight the impact of patient satisfaction and modern topical formulations on adherence and treatment outcomes.
Drug microencapsulation is a delivery technology that has enabled development of a topical fixed-dose combination of benzoyl peroxide and tretinoin preventing the oxidation of tretinoin by benzoyl peroxide and improving the tolerability of the active ingredients.
局部治疗仍然是痤疮和玫瑰痤疮患者治疗的主要手段。然而，新出现的真实世界证据表明，如果患者满意度和依从性较低，可能无法实现理想的治疗效果。活性药物和赋形剂成分及/或给药系统的耐受性差可能会对依从性产生负面影响。此外，涉及多种局部制剂应用的复杂治疗方案的依从性可能更低。优化赋形剂耐受性并简化使用固定剂量组合的方案可能会改善治疗效果、提高患者满意度并降低总体治疗成本。本定性综述讨论了几种旨在提高患者满意度和依从性的创新给药技术和制剂。
作者检索了临床研究中使用的当前和新兴局部给药技术，回顾了局部剂型化学特性的原始文献，并比较了对痤疮和玫瑰痤疮治疗效果的影响。
本文深入探讨了已出现的创新赋形剂和给药系统，这些系统允许不相容活性药物的固定剂量组合，并提高了既往有刺激性活性成分的耐受性。
需要进一步研究以充分突出患者满意度和现代局部制剂对依从性和治疗效果的影响。
药物微囊化是一种给药技术，它能够开发出一种过氧化苯甲酰和维甲酸的局部固定剂量组合，防止维甲酸被过氧化苯甲酰氧化，并提高活性成分的耐受性。
